Key clinical point: A triplet of targeted agents ublituximab, umbralisib, and ibrutinib may be an effective, nonchemotherapeutic regimen for patients with B-cell malignancies.
Major finding: Out of 44 patients, 37 (84%) achieved a partial or complete response to therapy.
Study details: A phase 1, multicenter, dose-escalation and dose-expansion trial involving 46 patients with chronic lymphocytic leukemia, small lymphocytic leukemia, or relapsed/refractory non-Hodgkin lymphoma.
Disclosures: The study was funded by TG Therapeutics. The authors reported financial relationships with TG Therapeutics and other companies.
Nastoupil LJ et al.